some reason modern medicine has itself turned a corner and entered
a darkness and is now committing crimes against humanity unequalled
in the history of our race."
--Dr. Mark Sircus
Alternative Cancer Treatments
by DIANNE JACOBS THOMPSON (under
1979 Around January of that year, I went
home to die.
I was diagnosed with stage 2 stomach cancer, chronic bronchitis,
acutely infected ovarian cysts, arthritis, sciatica, low thyroid,
anemia and a heart condition. Besides that I had chronic ear infections
and long-standing clinical depression. The late Dr.
Harold Dick, N.D., known as a "naturopathic oncology pioneer"
cured me in 5 weeks. It required the diagnosis (the Carroll
Food Test) of digestive enzyme
deficiency food intolerances which most people have and few
know about, and it also identified the primary tissue
salt deficiency, along with treatment with glandular
protomorphogens to restore glandular health, and Constitutional
Hydrotherapy to bring about detoxification, to stimulate blood
circulation and the activity of the vital organs and to jump-start
the immune system. It turned out to be the basic foundation of the
most successful healing system I've ever witnessed.
1986 My 5-year-old daughter was forcibly vaccinated
and immediately developed a flesh-eating
infection so virulent that my husband and I became infected
from contact. Naturopathic medicine brought us back from the brink.
Later that year
we were introduced to escharotic
cancer salves and treated a dog tumor, my husband's cirrhosis
of the liver, various skin lesions, moles, fungal infections, and
a lump in my thigh. It eventually
helped clear up the remaining symptoms from my husband's flesh-eating
infection after he was forced to submit to antibiotic treatment
which made a mess of it. There was much more, gallbladder
problems in 1999, adrenal
deficiency 2001, injury in 2002, arthritis,
diabetes, and other issues between
2003-2012, including glaucoma--cured.
why I research and write about alternative medicine. It's a debt.
treatments for cancer, chronic-degerative disease, infection, stress,
harmful emotions and other disorders and conditions;
junk science and bad medicine, including unsafe and ineffective vaccines
and undiagnosed medical conditions mimicking child abuse and Shaken Baby
site provides starting points. The rest of the journey must be yours.
"Truth wears no mask, seeks neither place nor
bows to no human shrine; she only asks a hearing"
VITAMIN C TRIALS IN THE TREATMENT OF CANCER
Vitamin C Trials in the Treatment of Cancer
With Oral and Intravenous Antioxidants--Dr. Moss Reports
"THE MOSS REPORTS
"For the past thirty years
I have been studying and closely monitoring
the world of cancer treatment, sorting fact from fiction, and helping
cancer patients and their families to understand and weigh the usefulness
of the treatments they have been offered.
The Moss Reports represent
a comprehensive library of cancer guides. In
them, my years of experience in researching cancer treatments have been
distilled into a careful assessment of the worth and effectiveness of
the conventional and alternative treatments of over two hundred
different kinds of cancer.
If you or someone you love
has received a diagnosis of cancer, a Moss
Report can provide you with the key to understanding the best that
conventional and alternative medicine have to offer. You can order a Moss
Report on your specific cancer type by calling Diane at 1-800-980-1234
(814-238-3367 from outside the US), or by visiting our website:
We look forward to helping
VITAMIN C AND CANCER: NEW DEVELOPMENTS
Vitamin C is in the news again. A study carried out by a research team
from the Harvard School of Public Health and published July 1 in the
New England Journal of Medicine (Fawzi, WW, 2004) showed that a
multivitamin supplement that included vitamin C significantly slowed the
of AIDS and provided an "effective, low-cost means of delaying the
initiation of antiretroviral therapy in HIV-infected women." The
of the treatment was estimated by the researchers to be about $15 per
year. Here is yet another demonstration of the astonishing power of food
supplements, particularly antioxidants such as vitamin C, to promote
I am often asked whether or
not vitamin C (ascorbic acid) is also an
effective way of fighting cancer. I answer that while there is a growing
body of scientific evidence to suggest that vitamin C is useful in the
prevention of cancer, the jury is still out on its effectiveness as a
cancer treatment. However, its low cost and astonishing lack of
toxicity make it an extremely attractive candidate for further testing.
Representative of the investigations
that are currently under way
concerning vitamin C's role in the treatment of cancer is the work of
N. Prasad, PhD, a professor of radiology at the University of Colorado
Health Sciences Center, Denver. Prasad has demonstrated that vitamin C
is capable of inhibiting the growth of cancer cells in vitro. He
advocates giving vitamin C and other antioxidants to patients while they
undergoing conventional chemotherapy and radiation. (I draw on his work
in my book Antioxidants Against Cancer.)
Click or go here for more information
on my book, Antioxidants Against
Prasad's theory is that normal
cells require only a minute, precisely
controlled amount of antioxidants in order to function. They reject any
excess. But among other defects, malignant cells have lost the capacity
to regulate their uptake of antioxidants such as vitamin C and E.
Antioxidants can therefore accumulate in cancer tissue in levels that
lead to the breakdown and death of malignant cells (Prasad 2003).
The history of research into
vitamin C as a cancer treatment is clouded
with controversy. In the 1970s, a Scottish physician Ewan Cameron, MD,
teamed up with Linus Pauling, PhD, to write a book, Cancer and Vitamin
C, in which they extolled the usefulness of vitamin C as a treatment
for cancer. (Pauling had previously published a book on vitamin C and
common cold.) Cancer and Vitamin C became a bestseller and this fueled
public demand for investigation of the role of vitamin C in cancer
Pauling was a world-famous
chemist, a two-time Nobel laureate, with
great medical achievements to his record. But he was not a medical doctor,
and this raised the ire of some medical critics such as the
self-proclaimed "quackbuster" Victor Herbert, MD. However, the
demand for a fair
test of Pauling's thesis could not be ignored indefinitely, and in time
doctors at the Mayo Clinic, Rochester, MN, undertook a clinical trial
that was supposed to replicate Drs. Cameron and Pauling's protocol.
In two often-cited papers,
Charles Moertel, MD and his Mayo colleagues
claimed that vitamin C had absolutely no beneficial effect when used in
the treatment of patients with advanced cancer, regardless of whether
or not they had received prior chemotherapy (Creagan 1979 and Moertel
1985). Dr. Moertel was called the "foremost professional demolition
expert...of alternative cancer treatments" (Richards 1991). Moertel's
negative comments on the topic included his assertion that evaluating
alternative treatments was a "waste of time and money...a waste of
hope" (Moertel 1989). His high-handed manner of testing vitamin C
convinced proponents that they had been set up for inevitable defeat.
damage had been done, and vitamin C was marginalized as a cancer
Tale of Two Trials
Is there a good scientific reason why vitamin C might have failed to
show a beneficial effect in the Mayo Clinic trials while succeeding in
the hands of its proponents? It now appears that there was. In the Mayo
Clinic studies all patients received either vitamin C tablets or an
inert sugar pill. What was widely overlooked at the time was that patients
on the Cameron-Pauling protocol were given vitamin C not only orally
but also via intravenous injection.
A few practitioners—most
notably Abram Hoffer, MD of Victoria, British
Columbia and Hugh Riordan, MD of the Center For the Improvement Of
Human Functioning International in Wichita, Kansas— continue to
C intravenously at doses of up to 100 grams – almost 4 ounces -
day. In fact, using high-dose intravenous vitamin C has become a common
procedure among CAM-oriented doctors, although it is ignored by orthodox
medicine – witness the fact that in the decade since 1994 the number
presentations on intravenous vitamin C at the American Society of
Clinical Oncology (ASCO) convention has been exactly zero.
New NIH Data
Could the route of administering vitamin C make a significant
difference? Yes it could. New data shows that how one gives ascorbic acid
big impact on the amount that actually becomes physiologically
available. An April, 2004 study by scientists at the US National Institutes
Health (NIH) showed that much more vitamin C gets taken up when it is
given via the intravenous route than when the vitamin is taken orally.
The authors of the study include Sebastian J. Padayatty, MD of the
Molecular and Clinical Nutrition Section at one of the NIH institutes,
his chief, Mark A. Levine, MD. Both are highly regarded figures in
academic circles. Dr. Levine is a Harvard Medical School graduate who
carried out the laboratory work that convinced the National Academy of
Science to increase of the recommended daily allowance (RDA) of vitamin
(In 2000, the RDA for men was increased from 60 to 90 mg daily, and for
women the RDA was increased from 60 to 75 mg daily.)
In the Padayatty study, 17
healthy hospitalized volunteers were given
either oral or intravenous doses of vitamin C, and blood plasma levels
were calculated for a dose range of 1 to 100 grams. The authors reported
that "peak plasma vitamin C concentrations were higher after
administration of intravenous doses than after administration of oral
the difference increased according to dose."
In fact, the blood concentration
of Vitamin C when given intravenously
was 6.6 times greater than when the same amount was given orally.
However, this hardly tells the full story. The maximum tolerated doses
differed significantly according to whether the vitamin C was
administered orally or intravenously. The maximum tolerated oral dose
calculated to be three grams every four hours, but when the vitamin C
given intravenously the researchers found they could give a 50 gram dose
in the same period. Furthermore, plasma concentrations up to sixty
times greater could be achieved using the intravenous route.
These NIH scientists observed
that oral vitamin C "produces plasma
concentrations that are tightly controlled… Only intravenous administration
of vitamin C produces high plasma and urine concentrations that might
have antitumor activity." They conclude that "the efficacy of
treatment cannot be judged from clinical trials that use only oral
dosing," as the Mayo Clinic studies most conspicuously did, and that
role of vitamin C in cancer treatment should be reevaluated" (Padayatti
2004). Coming from such prestigious government scientists, publishing
in the Annals of Internal Medicine, I believe this is a convincing
(albeit belated) refutation of the poorly designed Mayo Clinic studies.
It is never easy to arrange
clinical trials, especially of an agent
that has long been in the public domain and from whose sale no
super-profits can be expected. The way the drug approval system works
United States virtually requires the enthusiastic support of sponsors
deep pockets (which almost invariably means a pharmaceutical company)
order to see a new drug through the long, involved and expensive
process of drug approval. No non-toxic, readily available agent has ever
approved by the Food and Drug Administration for the treatment of
cancer. Vitamin C at retail sells for around five cents per gram. The
of even 100 grams prepared for intravenous use is still very inexpensive
compared to patented chemotherapy. I therefore don't think you will
find many drug companies lining up to test and market such a readily
available agent. And so the question of what vitamin C can do for
patients—so fascinating and promising—has remained in limbo.
However, things may be about
to change. At a meeting of the American
College for the Advancement of Medicine (ACAM) in April, 2003, Jeanne
Drisko, MD, announced just such a clinical trial at her institution,
the University of Kansas Medical Center. Luckily, the Cancer Treatment
Research Foundation (CTRF) stepped forward to fund the Kansas City
clinical trial. A randomized controlled trial, with Dr. Drisko as principal
investigator, is now underway at the University of Kansas Medical
Center, evaluating the safety and efficacy of antioxidants when added
chemotherapy in newly diagnosed ovarian cancer (Drisko 2003).
In a recent letter, Dr. Drisko
wrote: "This is a randomized study in
newly diagnosed ovarian cancer (Stage III or IV). The study subjects are
randomized to receive either first-line chemotherapy or first-line
chemotherapy along with high-dose antioxidants. The antioxidants are given
both orally and intravenously. If randomized to the antioxidant arm,
patients receive daily oral vitamins A, C, E and carotenoids, and
intravenous (IV) vitamin C 2 times per week for 12 months. We tailor the
of the IV vitamin C to their plasma vitamin C level - we try to get…the
neoplastic cell kill dose, using Dr. Hugh Riordan's protocol.
"At this plasma level,
vitamin C is chemotoxic to the cancer cells and
appears to be non-toxic to healthy cells. But we are following white
cell and platelet counts and other markers for possible toxicity from
vitamin C. Most patients need between 75 and 100 grams infused to get
to that plasma level. We can assure concerned oncologists that it
preliminarily does not appear that the high-dose antioxidants are interfering
with the chemotherapy at this time.
"In ovarian cancer," she continued, "the patients are usually
with chemotherapy during the first 5 to 6 months (6 cycles of
carboplatin and paclitaxel) so they are getting an additional 6 to 7 months
antioxidants past the chemo. This study is conducted under the oversight
of the FDA with an Investigative Drug (IND) number and has approval
from the Human Subjects Committee (i.e., the institutional review board)
of the University of Kansas Medical Center. So far, we have 14 patients
enrolled and are hoping to recruit 40. We have had 2 dropouts: 1
because she refused to adhere to the treatment requirements and started
smoking, and 1 because she was chemotherapy resistant to all chemotherapy
drug assays" (Drisko 2004).
This trial is a very encouraging
development. Dr. Drisko is a person
with credibility in both orthodox and CAM circles. She is thus in an
ideal position to do a study that will be not only rigorous but entirely
believable in its conclusions.
As some of you know, I wrote
the authorized biography of Albert
Szent-Gyorgyi, MD, PhD, who won the 1937 Nobel Prize for his discovery
vitamin C. In fact, it was he who named the vitamin ascorbic acid and
predicted its use in cancer. When Szent-Gyorgyi was on his deathbed, at
the age of 93, Linus Pauling flew from California to Szent-Gyorgi's
home at Woods Hole, Mass., to say goodbye. Holding his hand, Linus said
wistfully, "You know, Albert, I always thought that someday we two
work together." Szent-Gyorgyi looked up and said, humorously, "Well,
if not in this life, then maybe in the next." Pauling himself died
years later, also at age 93. They were two of the greatest thinkers of
the 20th century and it was one of the great privileges of my life to
know them both. I like to think of the two of them smiling down at this
latest development in the fascinating saga of this amazing chemical.
To find out more about the
Kansas clinical trial of vitamin C, contact:
Jeanne Drisko, MD
Program in Integrative Medicine
Functional Medicine and Complementary and Alternative Therapies
University of Kansas Medical Center
Kansas City, KS 66160
--Ralph W. Moss, PhD
American College of Physicians
(ACP). How vitamin C is administered
affects how much reaches the bloodstream and may affect the results of
studies of its potential effect on cancer. Annals of Internal Medicine,
Summaries for Patients, April 6, 2004. Retrieved July 1, 2004 from:
Drisko JA, Chapman J, Hunter
VJ. The use of antioxidants with
first-line chemotherapy in two cases of ovarian cancer. J Am Coll Nutr.
Drisko JA. Personal communication,
July 1, 2004.
Fawzi WW, et al. A randomized
trial of multivitamin supplements and HIV
disease progression and mortality N Engl J Med 2004;351:23-32.
Moertel, C.G. Interview on
'Health Report', ABC National Radio, August
7, 1989 [cited in Richards].
Padayatty SJ, et al. Vitamin
C pharmacokinetics: implications for oral
and intravenous use. Ann Intern Med. 2004 Apr 6;140(7):533-7.
Prasad KN. Antioxidants in
cancer care: when and how to use them as an
adjunct to standard and experimental therapies. Expert Rev Anticancer
Ther. 2003 Dec;3(6):903-15.
Richards, Evelleen. Vitamin
C and Cancer: Medicine or Politics? New
York: St. Martin's Press, 1991."
Thompson Est. 2003
The Misdiagnosis of
"Shaken Baby Syndrome" --an unproven theory without scientific
support, now in disrepute and wreaking legal and medical havoc world-wide
Author publication: NEXUS MAGAZINE "Seawater--A
Safe Blood Plasma Substitute?"
The material on this site is for informational and educational
purposes only. Please consult with your health care provider for treatment
Fight Spam! Click Here!